These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 25370598)

  • 1. Vision in a phase 3 trial of natalizumab for multiple sclerosis: relation to disability and quality of life.
    Chahin S; Balcer LJ; Miller DM; Zhang A; Galetta SL
    J Neuroophthalmol; 2015 Mar; 35(1):6-11. PubMed ID: 25370598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating loss of visual function in multiple sclerosis as measured by low-contrast letter acuity.
    Balcer LJ; Frohman EM
    Neurology; 2010 Apr; 74 Suppl 3():S16-23. PubMed ID: 20421569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life and its relationship to brain lesions and atrophy on magnetic resonance images in 60 patients with multiple sclerosis.
    Janardhan V; Bakshi R
    Arch Neurol; 2000 Oct; 57(10):1485-91. PubMed ID: 11030802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retinal atrophy in relation to visual functioning and vision-related quality of life in patients with multiple sclerosis.
    Balk LJ; Coric D; Nij Bijvank JA; Killestein J; Uitdehaag BM; Petzold A
    Mult Scler; 2018 May; 24(6):767-776. PubMed ID: 28511578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The King-Devick (K-D) test of rapid eye movements: a bedside correlate of disability and quality of life in MS.
    Moster S; Wilson JA; Galetta SL; Balcer LJ
    J Neurol Sci; 2014 Aug; 343(1-2):105-9. PubMed ID: 24954088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS.
    Balcer LJ; Galetta SL; Polman CH; Eggenberger E; Calabresi PA; Zhang A; Scanlon JV; Hyde R
    J Neurol Sci; 2012 Jul; 318(1-2):119-24. PubMed ID: 22521274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Color vision is strongly associated with retinal thinning in multiple sclerosis.
    Villoslada P; Cuneo A; Gelfand J; Hauser SL; Green A
    Mult Scler; 2012 Jul; 18(7):991-9. PubMed ID: 22291035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related quality of life in multiple sclerosis: effects of natalizumab.
    Rudick RA; Miller D; Hass S; Hutchinson M; Calabresi PA; Confavreux C; Galetta SL; Giovannoni G; Havrdova E; Kappos L; Lublin FD; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Stuart WH; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA;
    Ann Neurol; 2007 Oct; 62(4):335-46. PubMed ID: 17696126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vision related quality of life in multiple sclerosis: correlation with new measures of low and high contrast letter acuity.
    Mowry EM; Loguidice MJ; Daniels AB; Jacobs DA; Markowitz CE; Galetta SL; Nano-Schiavi ML; Cutter GR; Maguire MG; Balcer LJ
    J Neurol Neurosurg Psychiatry; 2009 Jul; 80(7):767-72. PubMed ID: 19240050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis.
    Baier ML; Cutter GR; Rudick RA; Miller D; Cohen JA; Weinstock-Guttman B; Mass M; Balcer LJ
    Neurology; 2005 Mar; 64(6):992-5. PubMed ID: 15781814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis.
    Balcer LJ; Raynowska J; Nolan R; Galetta SL; Kapoor R; Benedict R; Phillips G; LaRocca N; Hudson L; Rudick R;
    Mult Scler; 2017 Apr; 23(5):734-747. PubMed ID: 28206829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relation of vision to global and regional brain MRI in multiple sclerosis.
    Wu GF; Schwartz ED; Lei T; Souza A; Mishra S; Jacobs DA; Markowitz CE; Galetta SL; Nano-Schiavi ML; Desiderio LM; Cutter GR; Calabresi PA; Udupa JK; Balcer LJ
    Neurology; 2007 Dec; 69(23):2128-35. PubMed ID: 17881718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relation of quantitative visual and neurologic outcomes to fatigue in multiple sclerosis.
    Chahin S; Miller D; Sakai RE; Wilson JA; Frohman T; Markowitz C; Jacobs D; Green A; Calabresi PA; Frohman EM; Galetta SL; Balcer LJ
    Mult Scler Relat Disord; 2015 Jul; 4(4):304-10. PubMed ID: 26195047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis.
    Phillips JT; Giovannoni G; Lublin FD; O'Connor PW; Polman CH; Willoughby E; Aschenbach W; Pace A; Hyde R; Munschauer FE
    Mult Scler; 2011 Aug; 17(8):970-9. PubMed ID: 21421809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early retinal atrophy predicts long-term visual impairment after acute optic neuritis.
    Sanchez-Dalmau B; Martinez-Lapiscina EH; Torres-Torres R; Ortiz-Perez S; Zubizarreta I; Pulido-Valdeolivas IV; Alba-Arbalat S; Guerrero-Zamora A; Calbet D; Villoslada P
    Mult Scler; 2018 Aug; 24(9):1196-1204. PubMed ID: 28669275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relations of low contrast visual acuity, quality of life and multiple sclerosis functional composite: a cross-sectional analysis.
    Schinzel J; Zimmermann H; Paul F; Ruprecht K; Hahn K; Brandt AU; Dörr J
    BMC Neurol; 2014 Feb; 14():31. PubMed ID: 24555757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite.
    Balcer LJ; Baier ML; Cohen JA; Kooijmans MF; Sandrock AW; Nano-Schiavi ML; Pfohl DC; Mills M; Bowen J; Ford C; Heidenreich FR; Jacobs DA; Markowitz CE; Stuart WH; Ying GS; Galetta SL; Maguire MG; Cutter GR
    Neurology; 2003 Nov; 61(10):1367-73. PubMed ID: 14638957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Social participation in patients with multiple sclerosis: correlations between disability and economic burden.
    Kwiatkowski A; Marissal JP; Pouyfaucon M; Vermersch P; Hautecoeur P; Dervaux B
    BMC Neurol; 2014 May; 14():115. PubMed ID: 24884720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of vision impairment in Multiple Sclerosis.
    Sanchez-Dalmau B; Martinez-Lapiscina EH; Pulido-Valdeolivas I; Zubizarreta I; Llufriu S; Blanco Y; Sola-Valls N; Sepulveda M; Guerrero A; Alba S; Andorra M; Camos A; Sanchez-Vela L; Alfonso V; Saiz A; Villoslada P
    PLoS One; 2018; 13(4):e0195856. PubMed ID: 29664921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical meaning of walking speed as measured by the timed 25-foot walk in patients with multiple sclerosis.
    Cohen JA; Krishnan AV; Goodman AD; Potts J; Wang P; Havrdova E; Polman C; Rudick RA
    JAMA Neurol; 2014 Nov; 71(11):1386-93. PubMed ID: 25178496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.